NextFin News - A dormant legislative relic from the final days of the Clinton administration has emerged as a central battleground in the second term of U.S. President Trump, as public health advocates and the administration itself weaponize the Data Quality Act (DQA) to reshape federal scientific standards. The law, originally tucked into a 2001 appropriations bill by Republican Congresswoman JoAnne Emerson, requires federal agencies to ensure the "quality, objectivity, utility, and integrity" of information they disseminate. While historically used by industry groups to stall environmental and tobacco regulations, the DQA is now being invoked to both justify and challenge the rapid policy shifts occurring within the Department of Health and Human Services (HHS).
Joshua Sharfstein, a Distinguished Professor at the Johns Hopkins Bloomberg School of Public Health and former principal deputy commissioner of the FDA, argues that the scientific community must now "learn to love" this law. Sharfstein, who has a long history of advocating for rigorous, evidence-based public health policy and served under the Obama administration, suggests that the DQA provides a rare administrative mechanism to slow down or block policies based on what he characterizes as insufficient or misleading information. His perspective reflects a growing tactical shift among public health experts who are seeking legal leverage against the administration’s "MAHA" (Make America Healthy Again) agenda.
The administration has already moved aggressively to use the DQA as a shield for its own controversial decisions. In late 2025, the Centers for Disease Control and Prevention (CDC) cited the Act as the legal basis for altering its website regarding the relationship between vaccines and autism. The updated language, which suggests that scientific studies have not ruled out a link, replaced long-standing consensus statements. HHS Secretary Robert F. Kennedy Jr. reportedly "personally instructed" these changes, bypassing the traditional peer-review and career-expert clearance processes that the DQA itself was designed to protect. This internal use of the law is viewed by critics as a selective application of "data quality" to favor specific political narratives over established scientific consensus.
The stakes of this administrative tug-of-war are high for the healthcare and pharmaceutical sectors. Over the first 25 years of the DQA’s existence, HHS received only 81 formal complaints. However, the pace of challenges is expected to accelerate as the administration implements sweeping changes, such as the May 2025 decision to remove COVID-19 vaccines from the recommended schedule for healthy children and pregnant women. While the DQA does not offer a direct path to judicial appeal—the agency generally has the final word—it mandates a public response within 60 days. This requirement creates a window for transparency that can be used to fuel media coverage and influence public opinion.
From a legal standpoint, DQA complaints may also serve as foundational evidence in broader litigation. Under the Administrative Procedure Act, courts can strike down federal policies deemed "arbitrary and capricious." A documented failure by an agency to follow its own data quality protocols or to provide a reasoned response to a DQA complaint could provide the "smoking gun" needed for a judge to stay a regulation. This was a factor in a March 2026 district court decision that reversed several HHS actions related to vaccine schedules, signaling that the judiciary is increasingly willing to scrutinize the data-driven justifications of executive actions.
However, the effectiveness of the DQA as a tool for the scientific community remains a subject of debate. Some legal experts caution that the law is a double-edged sword; the administration is currently seeking to expand DQA requirements in ways that could make the standard regulatory process even more cumbersome for future administrations. By raising the bar for what constitutes "quality" data, the administration could effectively paralyze the ability of career civil servants to issue warnings or guidance without exhaustive, multi-year vetting processes. This strategy, often referred to as "paralysis by analysis," was the original intent of the law’s industry-backed authors in 2001.
The current landscape suggests that the Data Quality Act has evolved from an obscure procedural hurdle into a primary instrument of administrative power. As the Trump administration continues to bypass traditional agency experts in favor of direct political appointments, the DQA provides the only remaining formal channel for the public and the scientific community to demand a record of the evidence being used. Whether the law will ultimately protect scientific integrity or serve as the mechanism for its dismantling depends on how aggressively it is contested in the administrative and judicial arenas.
Explore more exclusive insights at nextfin.ai.
